Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
BioCryst Pharma Enters into Licensing Agreement with Seqirus 11
Equity Offering 13
BioCryst Pharma Rises USD57.5 Million in Public Offering of Shares 13
BioCryst Pharma Raises USD92 Million in Public Offering of Shares 15
BioCryst Pharma Files Registration Statement to Raise Funds through Public Offering of Shares 17
BioCryst Pharma Prices Public Offering of Shares for USD45 Million 18
BioCryst Pharma Raises USD115 Million in Public Offering of Shares 20
BioCryst Pharma Completes Public Offering Of Shares For US$20.3 Million 22
BioCryst Pharmaceuticals Inc – Key Competitors 24
BioCryst Pharmaceuticals Inc – Key Employees 25
BioCryst Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Nov 06, 2018: BioCryst reports third quarter 2018 financial results 27
Aug 07, 2018: BioCryst Reports Second Quarter 2018 Financial Results 29
May 08, 2018: BioCryst Reports First Quarter 2018 Financial Results 31
Feb 27, 2018: BioCryst Announces Fourth Quarter and Full Year 2017 Financial Results 33
Nov 07, 2017: BioCryst Reports Third Quarter 2017 Financial Results 35
Aug 07, 2017: BioCryst Reports Second Quarter 2017 Financial Results 37
May 04, 2017: BioCryst Reports First Quarter 2017 Financial Results 39
Feb 27, 2017: BioCryst Reports Fourth Quarter and Full Year 2016 Financial Results 41
Corporate Communications 43
May 30, 2017: Robert A. Ingram Named Chairman of BioCryst Pharmaceuticals 43
Legal and Regulatory 44
Mar 23, 2018: Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals 44
Product News 45
10/04/2017: BioCryst Announces RAPIVAB (peramivir injection) Presentations at IDWeek 2017 45
09/21/2017: BioCrysts RAPIVAB (peramivir injection) Receives FDA Approval for a Pediatric Indication 46
06/05/2017: BioCryst Announces RAPIVAB Pediatric sNDA Acceptance 47
05/24/2018: BioCryst’s BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema 48
02/23/2018: The European Medicines Agency’s CHMP Recommends Marketing Authorisation for Alpivab 49
Product Approvals 50
Jan 30, 2017: BioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines Agency 50
Jan 08, 2017: BioCryst Receives Health Canada Approval for RAPIVAB for the Treatment of Influenza 51
Clinical Trials 52
May 29, 2018: BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress 52
Mar 15, 2018: BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema 53
Feb 28, 2018: BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema 54
Jan 05, 2018: BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva 55
Oct 27, 2017: BioCryst Announces Late Breaker Presentation of BCX7353 Phase 2 APeX-1 Trial Results at the ACAAI’s 2017 Annual Scientific Meeting 56
Sep 05, 2017: BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE 57
Aug 02, 2017: BioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks 59
May 25, 2017: BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial 60
Apr 12, 2017: BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks 61
Feb 27, 2017: BioCryst Reports Positive Interim Results from its APeX-1 Trial 62
Other Significant Developments 64
Jun 05, 2018: BioCryst Issues Letter to Stockholders Reiterating Upside Potential of Value-Enhancing Merger with Idera 64
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioCryst Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
BioCryst Pharma Enters into Licensing Agreement with Seqirus 11
BioCryst Pharma Rises USD57.5 Million in Public Offering of Shares 13
BioCryst Pharma Raises USD92 Million in Public Offering of Shares 15
BioCryst Pharma Files Registration Statement to Raise Funds through Public Offering of Shares 17
BioCryst Pharma Prices Public Offering of Shares for USD45 Million 18
BioCryst Pharma Raises USD115 Million in Public Offering of Shares 20
BioCryst Pharma Completes Public Offering Of Shares For US$20.3 Million 22
BioCryst Pharmaceuticals Inc, Key Competitors 24
BioCryst Pharmaceuticals Inc, Key Employees 25
BioCryst Pharmaceuticals Inc, Other Locations 26
BioCryst Pharmaceuticals Inc, Subsidiaries 26
List of Figures
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9